Volume 1 Issue 1
Present Pharmacological Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion
Central retinal vein occlusion (CRVO) is a common sight-threatening retinal vascular disorder, in which macular edema is the main cause of visual impairment. The pathophysiology of macular edema involves both the presence of inflammation and angiogenic stimulant regarding vascular endothelial growth factor (VEGF). Intravitreal injections of anti-VEGF, including ranibizumab bevacizuamb, pegaptanib,aflibercept are proven to be effective for treating macular edema resulting from CRVO. Intravitreal injections of corticosteroids, potent anti-inflammatory agents, such as dexamethasone implants and triamcinolone acetonide have been shown to have a beneficial effect on macular edema associated with CRVO.
KERATOCONUS: IN VITRO AND IN VIVO
Keratoconus (KC) is a degenerative disease of the front part of the eye, named cornea. KC has three major characteristics: 1) cornea thinning, 2) corneal bulging, and 3) corneal scarring. KC usually appears during puberty and can quickly progress to severe stages leading to blindness. Worldwide 1:2000 people are affected with more prominence in the South Asians, Eastern Mediterranean and North African populations. Despite significant efforts by corneal researchers, the pathophysiology of the disease is still unknown, due in part to the absence of an animal model that can replicate KC.